Clinical Trial

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

Name: Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma — clinical trial record (NCT07270835)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

For patients who met the inclusion criteria, treatment regimens were administered: Rituximab 375 mg/m², intravenously, once weekly for 4 weeks. Zanubrutinib 160 mg, orally, twice daily for 4 weeks. Combined drugs: prednisone 100 mg/m²/d, orally, d1-5; Ruxolitinib 15mg bid orally; With/without emapalumab as appropriate.

Trial Details

NCT Number	NCT07270835
Lead Sponsor	The First Affiliated Hospital of Soochow University
Conditions	Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
Enrollment	40 participants
Start Date	2025-11-01
Primary Completion	2027-04 (estimated)
Study Completion	2027-08 (estimated)
Updated on ClinicalTrials.gov	2025-12-08